Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of E2082 in Healthy Males
NCT03402178Phase 1Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy comparing E2082 with Placebo (2 arms). Primary endpoints: Maximum Observed Concentration at Day 15, Time to Maximum Concentration at Day 15 and 5 more. Started Dec 2017; status: terminated.
02
Drugs
e2082
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03402178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03402178.